PSMG3
| Official symbol: | PSMG3 |
| Full name: | proteasome assembly chaperone 3 |
| Location: | 7p22.3 |
| Also known as: | PAC3, MGC10911, C7orf48 |
| Entrez ID: | 84262 |
| Ensembl ID: | ENSG00000157778 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.43 | | Gscore (Del): | 0.39 |
|
|
| Recurrently amplified in 3 cancer type(s) | | Recurrently deleted in 1 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 1 |
|
|
| Fusions detected in 1 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
CRISPR: COMMON ESSENTIAL
|
|
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 31.18 (Percentile rank: 54.63%) |
| PubTator score: | 13.52 (Percentile rank: 45.28%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Predicted TractableTargets with a predicted Ro5 druggable domain (druggable genome); Targets with a drugEBIlity score equal or greater than 0 |
| Tractability (antibody): | |
